These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 20212176)

  • 1. Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years.
    ; Lodwick R; Costagliola D; Reiss P; Torti C; Teira R; Dorrucci M; Ledergerber B; Mocroft A; Podzamczer D; Cozzi-Lepri A; Obel N; Masquelier B; Staszewski S; García F; De Wit S; Castagna A; Antinori A; Judd A; Ghosn J; Touloumi G; Mussini C; Duval X; Ramos J; Meyer L; Warsawski J; Thorne C; Masip J; Pérez-Hoyos S; Pillay D; van Sighem A; Lo Caputo S; Günthard H; Paredes R; De Luca A; Paraskevis D; Fabre-Colin C; Kjaer J; Chêne G; Lundgren JD; Phillips AN
    Arch Intern Med; 2010 Mar; 170(5):410-9. PubMed ID: 20212176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of antiretroviral third agent virologic durability after initiation of first antiretroviral regimen.
    Varriano B; Sandler I; Loutfy M; Steinberg S; Smith G; Kovacs C; Brunetta J; Fletcher D; Knox D; Merkley B; Chang B; Tilley D; Acsai M; Crouzat F
    Int J STD AIDS; 2019 Jun; 30(7):680-688. PubMed ID: 31042101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen.
    Gianotti N; Galli L; Galizzi N; Ripa M; Andolina A; Nozza S; Spagnuolo V; Poli A; Lazzarin A; Castagna A
    Int J Antimicrob Agents; 2018 Oct; 52(4):492-499. PubMed ID: 30009958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe.
    Judd A; Lodwick R; Noguera-Julian A; Gibb DM; Butler K; Costagliola D; Sabin C; van Sighem A; Ledergerber B; Torti C; Mocroft A; Podzamczer D; Dorrucci M; De Wit S; Obel N; Dabis F; Cozzi-Lepri A; García F; Brockmeyer NH; Warszawski J; Gonzalez-Tome MI; Mussini C; Touloumi G; Zangerle R; Ghosn J; Castagna A; Fätkenheuer G; Stephan C; Meyer L; Campbell MA; Chene G; Phillips A;
    HIV Med; 2017 Mar; 18(3):171-180. PubMed ID: 27625109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effectiveness of initiating non-nucleoside reverse transcriptase inhibitor- versus ritonavir-boosted protease inhibitor-based antiretroviral therapy: implications for first-line therapy choice in resource-limited settings.
    Lima VD; Hull M; McVea D; Chau W; Harrigan PR; Montaner JS
    J Int AIDS Soc; 2016; 19(1):20978. PubMed ID: 27499064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe.
    ; ; Nakagawa F; Lodwick R; Costagliola D; van Sighem A; Torti C; Podzamczer D; Mocroft A; Ledergerber B; Dorrucci M; Cozzi-Lepri A; Jansen K; Masquelier B; García F; De Wit S; Stephan C; Obel N; Fätkenhaeuer G; Castagna A; Sambatakou H; Mussini C; Ghosn J; Zangerle R; Duval X; Meyer L; Perez-Hoyos S; Fabre Colin C; Kjaer J; Chene G; Grarup J; Phillips A
    J Acquir Immune Defic Syndr; 2012 Mar; 59(3):294-9. PubMed ID: 22083070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of single and boosted protease inhibitor versus nonnucleoside reverse transcriptase inhibitor-containing cART regimens in antiretroviral-naïve patients starting cART after January 1, 2000.
    Mocroft ; Horban ; Clumeck ; Stellbrink ; Monforte dA; Zilmer ; Kirk ; Gatell ; Phillips ; Lundgren ;
    HIV Clin Trials; 2006; 7(6):271-84. PubMed ID: 17208897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study.
    ; ; Costagliola D; Lodwick R; Ledergerber B; Torti C; van Sighem A; Podzamczer D; Mocroft A; Dorrucci M; Masquelier B; de Luca A; Jansen K; De Wit S; Obel N; Fätkenheuer G; Touoloumi G; Mussini C; Castagna A; Stephan C; García F; Zangerle R; Duval X; Pérez-Hoyos S; Meyer L; Ghosn J; Fabre-Colin C; Kjaer J; Chene G; Grarup J; Phillips A
    Lancet Infect Dis; 2012 Feb; 12(2):119-27. PubMed ID: 21988895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.
    Penazzato M; Prendergast AJ; Muhe LM; Tindyebwa D; Abrams E
    Cochrane Database Syst Rev; 2014 May; 2014(5):CD004772. PubMed ID: 24852077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of boosted protease inhibitor-based regimens in HIV type 1-infected patients who experienced virological failure with NNRTI-based antiretroviral therapy in a resource-limited setting.
    Siripassorn K; Manosuthi W; Chottanapund S; Pakdee A; Sabaitae S; Prasithsirikul W; Tunthanathip P; Ruxrungtham K;
    AIDS Res Hum Retroviruses; 2010 Feb; 26(2):139-48. PubMed ID: 20156097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials.
    Borges ÁH; Lundh A; Tendal B; Bartlett JA; Clumeck N; Costagliola D; Daar ES; Echeverría P; Gisslén M; Huedo-Medina TB; Hughes MD; Huppler Hullsiek K; Khabo P; Komati S; Kumar P; Lockman S; MacArthur RD; Maggiolo F; Matteelli A; Miro JM; Oka S; Petoumenos K; Puls RL; Riddler SA; Sax PE; Sierra-Madero J; Torti C; Lundgren JD
    Clin Infect Dis; 2016 Jul; 63(2):268-80. PubMed ID: 27090986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy.
    Humphreys EH; Chang LW; Harris J
    Cochrane Database Syst Rev; 2010 Jun; (6):CD006517. PubMed ID: 20556768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of virological failure in HIV-1-infected patients experiencing low-level viraemia under active antiretroviral therapy (ANRS C03 cohort study).
    Vandenhende MA; Perrier A; Bonnet F; Lazaro E; Cazanave C; Reigadas S; Chêne G; Morlat P;
    Antivir Ther; 2015; 20(6):655-60. PubMed ID: 25735799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of triple-class virological failure in children with HIV: a retrospective cohort study.
    ; Castro H; Judd A; Gibb DM; Butler K; Lodwick RK; van Sighem A; Ramos JT; Warsawski J; Thorne C; Noguera-Julian A; Obel N; Costagliola D; Tookey PA; Colin C; Kjaer J; Grarup J; Chene G; Phillips A
    Lancet; 2011 May; 377(9777):1580-7. PubMed ID: 21511330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens.
    Zheng Y; Hughes MD; Lockman S; Benson CA; Hosseinipour MC; Campbell TB; Gulick RM; Daar ES; Sax PE; Riddler SA; Haubrich R; Salata RA; Currier JS
    Clin Infect Dis; 2014 Sep; 59(6):888-96. PubMed ID: 24842909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types.
    von Wyl V; Yerly S; Böni J; Bürgisser P; Klimkait T; Battegay M; Furrer H; Telenti A; Hirschel B; Vernazza PL; Bernasconi E; Rickenbach M; Perrin L; Ledergerber B; Günthard HF;
    Arch Intern Med; 2007 Sep; 167(16):1782-90. PubMed ID: 17846398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy.
    ;
    Clin Infect Dis; 2010 May; 50(9):1275-85. PubMed ID: 20353366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
    Hammer SM; Vaida F; Bennett KK; Holohan MK; Sheiner L; Eron JJ; Wheat LJ; Mitsuyasu RT; Gulick RM; Valentine FT; Aberg JA; Rogers MD; Karol CN; Saah AJ; Lewis RH; Bessen LJ; Brosgart C; DeGruttola V; Mellors JW;
    JAMA; 2002 Jul; 288(2):169-80. PubMed ID: 12095381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time to Switch to Second-line Antiretroviral Therapy in Children With Human Immunodeficiency Virus in Europe and Thailand.
    European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) Study Group in EuroCoord
    Clin Infect Dis; 2018 Feb; 66(4):594-603. PubMed ID: 29029056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.
    Sungkanuparph S; Overton ET; Seyfried W; Groger RK; Fraser VJ; Powderly WG
    Clin Infect Dis; 2005 Nov; 41(9):1326-32. PubMed ID: 16206110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.